

**In the Claims:**

Claims 1-24 (Cancelled)

25. (Currently Amended): An isolated polypeptide comprising a member selected from the group consisting of

- (a) ~~the an~~ amino acid sequence SEQ ID NO:2 ~~matching one of SEQ ID NOs:2 (BASB082), 4 (BASB083), 6 (BASB091), 8 (BASB092) and 10 (BASB101); and~~
- (b) an immunogenic ~~polypeptide comprising a fragment sequence~~ of at least 15 contiguous amino acids of SEQ ID NO:2 ~~that matches an aligned contiguous segment of one of SEQ ID NOs: 2, 4, 6, 8 and 10;~~

wherein the immunogenic fragment ~~isolated polypeptide~~, when administered to a subject in a suitable composition which can include an adjuvant, or a suitable carrier coupled to the polypeptide, induces an antibody or T-cell mediated immune response that recognizes the ~~to a~~ polypeptide SEQ ID NO:2 ~~having the sequence of one of SEQ ID NOs:2, 4, 6, 8 and 10.~~

26. (Cancelled)

27. (Previously Presented): The isolated polypeptide of claim 25, wherein the polypeptide is according to (a).

28. (Cancelled)

29. (Previously Presented): The isolated polypeptide of claim 25, wherein the polypeptide is according to (b).

30. (Cancelled)

31. (Currently Amended): The isolated polypeptide of claim 25, wherein the immunogenic fragment of (b) comprises at least 20 contiguous amino acids of SEQ ID NO:2, wherein the

immunogenic fragment, when administered to a subject in a suitable composition which can include an adjuvant, or a suitable carrier coupled to the polypeptide, induces an antibody or T-cell mediated immune response that recognizes the polypeptide SEQ ID NO:2.

32. (Currently Amended): The isolated polypeptide of Claim 25 wherein the isolated polypeptide ~~of (a)~~ consists of SEQ ID NO:2 ~~one of SEQ ID NOs:2, 4, 6, 8 and 10.~~

Claims 33-34 (Cancelled)

35. (Previously Presented): A fusion protein comprising the isolated polypeptide of Claim 25.

Claims 36-39 (Cancelled)

40. (Currently Amended): An immunogenic composition ~~A vaccine~~ comprising the polypeptide of Claim 25 and a pharmaceutically acceptable carrier.

41. (Currently Amended): The immunogenic composition ~~vaccine~~ of Claim 40, wherein the immunogenic composition ~~vaccine~~ comprises at least one other *Neisseria meningitidis* antigen.

42. (Cancelled)

43. (Previously Presented): A method for inducing an immune response in a mammal comprising administration of the polypeptide of Claim 25.

Claims 44-46 (Cancelled)

47. (New): The isolated polypeptide of Claim 25, wherein the isolated polypeptide is a recombinant polypeptide.

48. (New): A fusion protein comprising the isolated polypeptide of Claim 27.

49. (New): An immunogenic composition comprising the isolated polypeptide of Claim 27.
50. (New): A fusion protein comprising the isolated polypeptide of Claim 29.
51. (New): An immunogenic composition comprising the isolated polypeptide of Claim 29.